Skip to main
ATNM
ATNM logo

Actinium Pharmaceuticals (ATNM) Stock Forecast & Price Target

Actinium Pharmaceuticals (ATNM) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actinium Pharmaceuticals Inc. holds a positive outlook due to promising developments in its drug candidate Actimab-A, which shows potential to enhance the efficacy of established checkpoint inhibitors by selectively depleting myeloid-derived suppressor cells (MDSCs) in solid tumors. The engagement in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute has positioned Actinium to pursue innovative clinical trials while benefiting from substantial cost savings. The anticipation of initial proof-of-concept data in the second half of 2025 further underscores the company’s strategic advancement and bolsters investor confidence in its future performance.

Bears say

Actinium Pharmaceuticals Inc faces significant risks that could negatively impact its stock performance, primarily due to the possibility of failed or inconclusive clinical trials for its product candidates, Iomab-B and Actimab-A. Additionally, the company's ability to secure adequate funding is a critical factor that could hinder the progression of its drug development pipeline. Despite a notable unmet medical need for effective therapies in acute myeloid leukemia, the lack of financial stability and the uncertainty surrounding clinical outcomes present substantial challenges for the company's future growth prospects.

Actinium Pharmaceuticals (ATNM) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actinium Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actinium Pharmaceuticals (ATNM) Forecast

Analysts have given Actinium Pharmaceuticals (ATNM) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Actinium Pharmaceuticals (ATNM) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actinium Pharmaceuticals (ATNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.